PT1216707E - Novas utilizacoes terapeuticas para um smr-1-peptideo - Google Patents
Novas utilizacoes terapeuticas para um smr-1-peptideoInfo
- Publication number
- PT1216707E PT1216707E PT00403670T PT00403670T PT1216707E PT 1216707 E PT1216707 E PT 1216707E PT 00403670 T PT00403670 T PT 00403670T PT 00403670 T PT00403670 T PT 00403670T PT 1216707 E PT1216707 E PT 1216707E
- Authority
- PT
- Portugal
- Prior art keywords
- peptideo
- smr
- utilizations
- new therapeutic
- smr1
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
- G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00403670A EP1216707B1 (en) | 2000-12-22 | 2000-12-22 | Process for screening ligand molecules that specifically bind to the NEP binding site for the QHNPR pentapeptide |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1216707E true PT1216707E (pt) | 2005-06-30 |
Family
ID=8174003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT00403670T PT1216707E (pt) | 2000-12-22 | 2000-12-22 | Novas utilizacoes terapeuticas para um smr-1-peptideo |
Country Status (12)
Country | Link |
---|---|
US (4) | US7423020B2 (pt) |
EP (3) | EP1216707B1 (pt) |
JP (4) | JP4347566B2 (pt) |
CN (2) | CN1217190C (pt) |
AT (2) | ATE288763T1 (pt) |
AU (2) | AU2002234806A1 (pt) |
CA (2) | CA2431913A1 (pt) |
DE (2) | DE60018085T2 (pt) |
DK (1) | DK1216707T3 (pt) |
ES (2) | ES2235806T3 (pt) |
PT (1) | PT1216707E (pt) |
WO (2) | WO2002051434A2 (pt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6589750B2 (en) * | 1997-02-20 | 2003-07-08 | Institut Pasteur | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
DK1185294T3 (da) | 1999-06-23 | 2005-08-01 | Centre Nat Rech Scient | Peptider til behandling af svækkede interpersonelle og adfærdsmæssige lidelser |
ATE288763T1 (de) * | 2000-12-22 | 2005-02-15 | Pasteur Institut | Prozess zum screening von molekülen, die spezifisch an die nep-bindungsstelle des qhnpr- pentapeptides binden |
JP4002927B2 (ja) * | 2002-05-29 | 2007-11-07 | メルク エンド カムパニー インコーポレーテッド | 炭疸病治療および致死因子阻害に有用な化合物 |
MXPA05008097A (es) | 2003-01-28 | 2006-02-08 | Microbia Inc | Metodos y composiciones para el tratamiento de desordenes gastrointestinales. |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
ES2390075T3 (es) | 2004-03-19 | 2012-11-06 | Institut Pasteur | Péptidos derivados de la proteína BPLP humana, polinucleótidos que codifican dichos péptidos y anticuerpos dirigidos contra dichos péptidos |
EP1747212A4 (en) * | 2004-05-11 | 2009-03-25 | Merck & Co Inc | PROCESS FOR PRODUCING N-SULFINATED AMINO ACID DERIVATIVES |
US20100003276A1 (en) * | 2004-12-07 | 2010-01-07 | Hermes Jeffery D | Methods for treating anthrax and inhibiting lethal factor |
US7879802B2 (en) | 2007-06-04 | 2011-02-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US20100120694A1 (en) | 2008-06-04 | 2010-05-13 | Synergy Pharmaceuticals, Inc. | Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
JP5788788B2 (ja) * | 2008-04-07 | 2015-10-07 | アンスティテュ パストゥールInstitut Pasteur | エンケファリンを分解するエクトペプチダーゼを強力に阻害するオピオルフィンペプチド誘導体 |
FR2931362B1 (fr) | 2008-05-26 | 2017-08-18 | Pasteur Institut | L'opiorphine pour une utilisation en tant que psychostimulant. |
EP2321341B1 (en) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
CA2645452A1 (en) * | 2008-11-28 | 2010-05-28 | Institut Pasteur | Use of basic prolin-rich lacrimal gene products, such as opiorphin, as a biomarker |
CA2745694C (en) | 2008-12-03 | 2018-03-27 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase c agonists and methods of use |
US8506544B2 (en) | 2010-06-21 | 2013-08-13 | The Procter & Gamble Company | Disposable absorbent pant with efficient design and convenient single-section side stretch panels |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
MX357121B (es) | 2011-03-01 | 2018-06-27 | Synergy Pharmaceuticals Inc Star | Proceso de preparacion de agonistas c de guanilato ciclasa. |
EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
BR112015030326A2 (pt) | 2013-06-05 | 2017-08-29 | Synergy Pharmaceuticals Inc | Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US738778A (en) * | 1903-05-22 | 1903-09-15 | Cottrell C B & Sons Co | Sheet-delivery apparatus for printing and folding machinery. |
FI881869A (fi) * | 1987-04-25 | 1988-10-26 | Hoechst Ag | Enkastiner: nya glykopeptider med enkefalinashindrande verkan, foerfaranden foer deras framstaellning och deras anvaendning saosom farmaceutiska produkter. |
FR2637600B1 (fr) * | 1988-10-11 | 1992-03-06 | Pasteur Institut | Peptides et polypeptides provenant de la glande sous maxillaire du rat, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et applications de ces produits au diagnostic, a la detection ou a des fins therapeutiques |
US5550119A (en) * | 1995-03-02 | 1996-08-27 | Ciba-Geigy Corporation | Phosphono substituted tetrazole derivatives as ECE inhibitors |
US6589750B2 (en) * | 1997-02-20 | 2003-07-08 | Institut Pasteur | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
DK1185294T3 (da) * | 1999-06-23 | 2005-08-01 | Centre Nat Rech Scient | Peptider til behandling af svækkede interpersonelle og adfærdsmæssige lidelser |
ATE288763T1 (de) * | 2000-12-22 | 2005-02-15 | Pasteur Institut | Prozess zum screening von molekülen, die spezifisch an die nep-bindungsstelle des qhnpr- pentapeptides binden |
-
2000
- 2000-12-22 AT AT00403670T patent/ATE288763T1/de active
- 2000-12-22 ES ES00403670T patent/ES2235806T3/es not_active Expired - Lifetime
- 2000-12-22 PT PT00403670T patent/PT1216707E/pt unknown
- 2000-12-22 DE DE60018085T patent/DE60018085T2/de not_active Expired - Lifetime
- 2000-12-22 EP EP00403670A patent/EP1216707B1/en not_active Expired - Lifetime
- 2000-12-22 DK DK00403670T patent/DK1216707T3/da active
-
2001
- 2001-12-24 JP JP2002552576A patent/JP4347566B2/ja not_active Expired - Fee Related
- 2001-12-24 JP JP2002552577A patent/JP4409831B2/ja not_active Expired - Fee Related
- 2001-12-24 EP EP01985459A patent/EP1343519A2/en not_active Withdrawn
- 2001-12-24 AT AT01985936T patent/ATE497390T1/de active
- 2001-12-24 US US10/451,073 patent/US7423020B2/en not_active Expired - Fee Related
- 2001-12-24 AU AU2002234806A patent/AU2002234806A1/en not_active Abandoned
- 2001-12-24 AU AU2002236100A patent/AU2002236100A1/en not_active Abandoned
- 2001-12-24 CN CN018212654A patent/CN1217190C/zh not_active Expired - Fee Related
- 2001-12-24 WO PCT/IB2001/002818 patent/WO2002051434A2/en active Application Filing
- 2001-12-24 ES ES01985936T patent/ES2363708T3/es not_active Expired - Lifetime
- 2001-12-24 CA CA002431913A patent/CA2431913A1/en not_active Abandoned
- 2001-12-24 US US10/451,064 patent/US7153833B2/en not_active Expired - Lifetime
- 2001-12-24 WO PCT/IB2001/002819 patent/WO2002051435A2/en active Application Filing
- 2001-12-24 CA CA2431916A patent/CA2431916C/en not_active Expired - Lifetime
- 2001-12-24 EP EP01985936A patent/EP1343520B1/en not_active Expired - Lifetime
- 2001-12-24 DE DE60143990T patent/DE60143990D1/de not_active Expired - Lifetime
- 2001-12-24 CN CNB018212646A patent/CN1229137C/zh not_active Expired - Fee Related
-
2006
- 2006-11-08 US US11/594,105 patent/US7625713B2/en not_active Expired - Fee Related
-
2008
- 2008-06-06 JP JP2008149611A patent/JP2009007352A/ja active Pending
- 2008-11-28 JP JP2008305315A patent/JP2009149633A/ja active Pending
-
2009
- 2009-10-16 US US12/580,701 patent/US20100041072A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1216707E (pt) | Novas utilizacoes terapeuticas para um smr-1-peptideo | |
ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
BR0205722A (pt) | Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor | |
BR0108977A (pt) | Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina | |
BR0111358A (pt) | Compostos de tioacetamida e seu uso | |
EE200400020A (et) | Asendatud oksasolidinoonid kombineeritud raviks | |
ATE339187T1 (de) | Verwendung von zusammensetzungen mit antiseptika und/oder die wundheilung fördernden wirkstoffen für den tieferen atemwegstrakt | |
BR0110767A (pt) | Derivados de piperidina farmaceuticamente ativos, em particular como moduladores da atividade de receptor de quimiocina | |
DE602006016799D1 (de) | NEUE, HYALURONSÄURE ODER HYALURONSàURE DERIVATE UND COLLAGENASE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR TOPISCHEN BEHANDLUNG VON WUNDEN, VERBRENNUNGEN UND GESCHWÜREN | |
BR0316438A (pt) | Uso de eritropoietina em doenças cardìacas | |
DK1363608T3 (da) | Formuleringer omfattende ibuprofen og diphenhydramin og deres anvendelse til behandling af sovnforstyrrelser | |
PA8657201A1 (es) | Compuestos de 3h-oxazolo y 3h-tiazolo [4, 5-d] pirimidin-2-ona 3, 5-disustituida y 3, 5, 7 - trisustituida y profarmacos de los mismos | |
ATE247507T1 (de) | Verwndung von verbindungen mit 5-ht1a aktivität zur behandlung von krankheiten der äusseren retina | |
BRPI0410316A (pt) | composto, composição farmacêutica, uso dos compostos, e, método de tratamento de distúrbios mediados por vr1 e para o tratamento de distúrbios de dores | |
DE60123100D1 (de) | Honig enthaltende pharmazeutische zusammensetzung zur wundbehandlung | |
SE0102440D0 (sv) | New compound | |
BR0101486A (pt) | Composições farmacêuticas de uso tópico, aplicadas no tratamento de lesões de pele e/ou mucosas; uso das composições no tratamento de lesões de pele e/ou mucosas e uso de compostos no tratamento de lesões de pele e/ou mucosas | |
BR0012291A (pt) | Fenoxifluorpirimidinas | |
BRPI0408689A (pt) | derivados de benzenosulfonamida, método para preparação e utilização disso para o tratamento da dor | |
BRPI0411702A (pt) | uso de ácido hialurÈnico para preparar composições para o tratamento de aftas da cavidade oral | |
DE60019086D1 (de) | Zusammensetzungen zur behandlung von hautkrankheiten | |
ES2177849T3 (es) | Preparado farmaceutico, que contiene 2-fenil-1,2-benzoisoselenazol-3(2h)-ona, para el tratamiento de la enfermedad de alzheimer. | |
BR0009194A (pt) | Composição do resorcinol | |
ATE344662T1 (de) | Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen | |
SE0000303D0 (sv) | Novel compounds |